Literature DB >> 11001103

Persistently positive cultures and outcome in invasive neonatal candidiasis.

R L Chapman1, R G Faix.   

Abstract

BACKGROUND: A persistently positive culture >24 h after starting antibiotic therapy has been correlated with adverse outcome in several invasive bacterial infections, but few reports address persistent positivity and outcome in infections caused by fungi and other pathogens that replicate more slowly and therefore may succumb less quickly to therapy.
METHODS: To assess whether positive culture >24 h after achieving target doses (amphotericin > or =0.5 mg/kg/day or fluconazole > or =6 mg/kg/day) of systemic antifungal therapy predicts focal infectious complication(s) or death from infection, we compared neonatal intensive care unit infants who had persistent (P+) or nonpersistent (P-) positive cultures with invasive candidiasis (clinical signs of infection and recovery of Candida from a normally sterile site) at this center from January 1, 1981, through June 30, 1999. Infants who died < or = 24 h after attaining target dosing, recovered without therapy, had a focal infectious complication already present at the time target dosing was achieved or were diagnosed with invasive candidiasis only postmortem were excluded.
RESULTS: We identified 58 P+ (29, 12 and 7 had positive cultures for >7, >14 and > or =21 days, respectively) and 38 P- infants. No differences were found between P+ and P- for birth weight; gestational age; gender; onset age; central vascular catheters; necrotizing enterocolitis, surgery or bacterial sepsis; or duration of parenteral nutrition, antibiotics, tracheal intubation or postnatal steroids. P+ were more likely to have blood or cerebrospinal fluid involvement (68 vs. 45%, P = 0.03). Distribution of Candida species was similar (albicans in 53 vs. 63% for P+ vs. P-). P+ were significantly more likely to develop later "fungus ball" uropathy (16 of 56 vs. 2 of 32, P = 0.01), to develop renal infiltration (11 of 56 vs. 1 of 32, P = 0.03) and to die from invasive candidiasis (11 of 58 vs. 0 of 38, P = 0.003) than P-. P+ were also more likely to develop endocarditis, abscess, ventriculitis and invasive dermatitis, although P > 0.05. Focal complication increased as duration of P+ increased (48, 55, 67 and 71% at >1, >7, >14 and > or =21 days, P = 0.06). When comparing only those with positive blood and/or cerebrospinal fluid culture, similar patterns were observed, although only death and focal complication or death from invasive candidiasis attained significance.
CONCLUSIONS: These observations suggest that in neonatal invasive candidiasis: (1) cultures usually remain positive >24 h after attaining target antifungal doses; (2) aggressive imaging for focal complications may be reserved for infants with persistently positive cultures after several days of antifungal therapy at target doses or have signs strongly suggestive of focal complication; (3) focal complications and/or death from candidiasis increase with persistence; (4) focal complications increase with duration of persistence; (5) serial culture of infected site(s) helps predict outcome and the need for aggressive surveillance and intervention for focal complications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001103     DOI: 10.1097/00006454-200009000-00003

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  16 in total

1.  Recent Advances in the Detection of Neonatal Candidiasis.

Authors:  L Corbin Downey; P Brian Smith; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Curr Fungal Infect Rep       Date:  2010-03-01

2.  Coagulase-negative staphylococcal infections in the neonatal intensive care unit.

Authors:  Naomi Jean-Baptiste; Daniel K Benjamin; Michael Cohen-Wolkowiez; Vance G Fowler; Matthew Laughon; Reese H Clark; P Brian Smith
Journal:  Infect Control Hosp Epidemiol       Date:  2011-07       Impact factor: 3.254

3.  Survey of neonatal candidiasis in Greece.

Authors:  J Dotis; J Evdoridou; G Kremenopoulos; E Roilides
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

Review 4.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 5.  The iC3b receptor of Candida albicans and its roles in pathogenesis.

Authors:  Margaret K Hostetter
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

6.  High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates.

Authors:  A Juster-Reicher; O Flidel-Rimon; M Amitay; S Even-Tov; E Shinwell; E Leibovitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-09-12       Impact factor: 3.267

7.  Incidence and predictors of invasive candidiasis associated with candidaemia in children.

Authors:  Ara Festekjian; Michael Neely
Journal:  Mycoses       Date:  2011-03       Impact factor: 4.377

Review 8.  Treatment and prophylaxis of invasive candidiasis.

Authors:  Nidhi Tripathi; Kevin Watt; Daniel K Benjamin
Journal:  Semin Perinatol       Date:  2012-12       Impact factor: 3.300

9.  Intraocular infections in the neonatal intensive care unit.

Authors:  Hassan A Aziz; Audina M Berrocal; Robert A Sisk; Kristin Hartley; Magaly Diaz-Barbosa; Rose A Johnson; Ditte Hess; Sander R Dubovy; Timothy G Murray; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2012-05-14

Review 10.  The epidemiology and diagnosis of invasive candidiasis among premature infants.

Authors:  Matthew S Kelly; Daniel K Benjamin; P Brian Smith
Journal:  Clin Perinatol       Date:  2014-11-28       Impact factor: 2.642

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.